Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery
Publication
, Conference
Carrier, M; Taylor, KM; Haverich, A; Chen, JC; Shernan, SK; Newman, MF; Levy, JH; Van de Wert, F; van der Laan, M; Todaro, TG; Adams, PX; Verrier, ED
Published in: CIRCULATION
October 26, 2004
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
October 26, 2004
Volume
110
Issue
17
Start / End Page
672 / 672
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
77th Scientific Meeting of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Carrier, M., Taylor, K. M., Haverich, A., Chen, J. C., Shernan, S. K., Newman, M. F., … Verrier, E. D. (2004). Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery. In CIRCULATION (Vol. 110, pp. 672–672). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
Carrier, M., K. M. Taylor, A. Haverich, J. C. Chen, S. K. Shernan, M. F. Newman, J. H. Levy, et al. “Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery.” In CIRCULATION, 110:672–672. LIPPINCOTT WILLIAMS & WILKINS, 2004.
Carrier M, Taylor KM, Haverich A, Chen JC, Shernan SK, Newman MF, et al. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2004. p. 672–672.
Carrier, M., et al. “Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery.” CIRCULATION, vol. 110, no. 17, LIPPINCOTT WILLIAMS & WILKINS, 2004, pp. 672–672.
Carrier M, Taylor KM, Haverich A, Chen JC, Shernan SK, Newman MF, Levy JH, Van de Wert F, van der Laan M, Todaro TG, Adams PX, Verrier ED. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2004. p. 672–672.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
October 26, 2004
Volume
110
Issue
17
Start / End Page
672 / 672
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
77th Scientific Meeting of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology